一分钟看懂
这是一项关于Pheochromocytoma/Paraganglioma的II 期研究，登记的药物或干预包括Ivocizumab，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ivocizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Cancer Hospital · 上海
公开的入选条件
- * Individuals able to understand and give written informed consent.
- * Histologically or cytologically confirmed cancer of one of the following types:
- PAGET's disease of scrotum with infiltrating sweat gland carcinoma Paraganglioma Pheochromocytom, Renal angiomyolipoma Malignant perivascular epithelioid cell tumor, Rhabdomyosarcom Other sarcoma rather than rhabdomyosarcom
- * Stage IV disease
- * Adequate performance status (ECOG 0-2)
- * Expected survival ≥ 3 months.
- * Measurable disease by CT or MRI, Or lesions with skin infiltration.
- * Adequate hematology without ongoing transfusional support (hemoglobin \> 9 g/dL, absolute neutrophil count (ANC) \> 1,500 per mm\^3, platelets \> 100,000 per mm\^3).
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06683846；登记信息更新于 2025-08-24。